Analyst Ratings For Array BioPharma (NASDAQ:ARRY)
Today, Array BioPharma (NASDAQ:ARRY) stock received an upgrade by Leerink Swann from Market Perform to Outperform.
Some recent analyst ratings include
- 1/22/2018-Leerink Swann Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 11/1/2017-SunTrust Banks Reiterated Rating of Buy.
- 9/20/2017-Piper Jaffray Companies Reiterated Rating of Overweight.
- 9/11/2017-Cowen Reiterated Rating of Outperform.
Recent Insider Trading Activity For Array BioPharma (NASDAQ:ARRY)
Array BioPharma (NASDAQ:ARRY) has insider ownership of 3.18% and institutional ownership of 98.14%.
- On 1/17/2018 Lunsen Gil J Van, Director, sold 21,500 with an average share price of $12.94 per share and the total transaction amounting to $278,210.00.
- On 1/16/2018 Jason Haddock, CFO, sold 7,500 with an average share price of $13.73 per share and the total transaction amounting to $102,975.00.
- On 12/19/2017 Ron Squarer, CEO, sold 819,671 with an average share price of $10.86 per share and the total transaction amounting to $8,901,627.06.
- On 12/18/2017 Andrew R. Robbins, COO, sold 282,874 with an average share price of $10.72 per share and the total transaction amounting to $3,032,409.28.
- On 9/29/2017 Kyle Lefkoff, Director, sold 38,865 with an average share price of $12.31 per share and the total transaction amounting to $478,428.15.
- On 3/28/2017 Charles M Baum, Director, sold 25,000 with an average share price of $9.27 per share and the total transaction amounting to $231,750.00.
- On 9/28/2016 Redmile Group, Llc, Major Shareholder, sold 2,492,578 with an average share price of $6.36 per share and the total transaction amounting to $15,852,796.08.
Recent Trading Activity for Array BioPharma (NASDAQ:ARRY)
Shares of Array BioPharma closed the previous trading session at 14.33 up +1.19 9.04% with 14.260000228881836 shares trading hands.
